Walgreens, Prime Therapeutics to form AllianceRx Walgreens Prime
Walgreens and Prime Therapeutics LLC merge to offer specialty pharmacy and mail services Read More »
AbbVie's Imbruvica sNDA accepted for review by FDA
AbbVie's supplemental new drug application for ibrutinib, a product for treating chronic graft vs. host disease (cGVHD) after failure of one or more lines of systemic therapy, has received FDA approval. Read More »
Daiichi Sankyo enrolls first patient in Eliminate-AF study
Daiichi Sankyo Inc. recently announced the enrollment of the first person for its Eliminate-AF study. Read More »
Bracco Imaging invests in health technology company
Bracco Imaging has invested in PHS Technologies Group to solidify Bracco's role in the industry and increase the scope of its portfolio software applications related to dose management. Read More »
FDA approves application for breast cancer drug from Pfizer
Pfizer Inc.'s supplemental New Drug Application (sNDA) for Ibrance, its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, has been approved by the U.S. Food and Drug Administration. Read More »
Panacea Pharmaceuticals shares news about cancer biomarkers
Panacea Pharmaceuticals Inc. presented its paper, "Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase," and its findings on the company's multi-cancer HAAH exosome detection assay during the annual American Association for Cancer Research meeting in Washington, D.C. April 1-5. Read More »
Allergan uncovers potential for using Botox to treat depression
Popularly known for its ability to enhance facial appearance cosmetically, Botox is now under scrutiny for its possible application for treating major depressive disorder, based on data from a study undertaken by Allergan. Read More »
Panacea successfully targets, kills leukemia cells
The paper "Radioimmunotherapy for Acute Myeloid Leukemia Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase” was presented at the American Association for Cancer Research (AACR) meeting by Panacea Pharmaceuticals on April 3. Read More »
Purdue Pharma participates in North Carolina drug disposal program
Teaming up to enhance North Carolina’s public health outcomes, Purdue Pharma of Stamford, Connecticut; nationwide Project Lazarus; and Safe Kids North Carolina recently entered a three-way collaboration via the North Carolina Disposal Initiative (NCDI). Read More »
Teva drug approved to ease chorea in Huntington's patients
To treat some of Huntington disease’s harshest symptoms and help restore quality of life to those suffering from the rare, fatal neurodegenerative disease, the U.S. Food and Drug Administration recently approved a medication created by Teva Pharmaceutical Industries. Read More »
McKesson Corp. completes acquisition of CoverMyMeds
Health care supply distributor McKesson Corp. of San Francisco has completed its acquisition of CoverMyMeds LLC, an Ohio-based source of electronic authorization technology for medical providers and pharmacists. Read More »
Change Healthcare unveils latest clinical support solution
Change Healthcare recently announced the unveiling of InterQual 2017, the company’s flagship clinical decision support solution. Read More »
Phase 2 Evenity study shows promising results
Amgen and UCB recently announced that their phase 2 study for Evenity (romosozumab) showed positive fourth-year results for efficacy and safety as a second course of treatment for postmenopausal women with osteoporosis. Read More »
Bristol-Myers and Incyte to launch Phase 3 studies of drug combination
Bristol-Myers Squibb Co. and Incyte Corp. have agreed to advance their clinical development program. Read More »
Amgen files requests to expand Xgeva's use in U.S. and Europe
Amgen recently announced that the company submitted to the U.S. Food and Drug Administration (FDA) a supplemental Biologics License Application (sBLA) for Xgeva (denosumab). The company also seeks approval from the European Medicines Agency (EMA). Read More »
Review of brexpiprazole anticipated by European authority
The European Medicines Agency has accepted a Marketing Authorization Application for brexpiprazole, and its review is anticipated in the second quarter of 2018. Read More »
District Court in Delaware invalidates four Ampyra patents
Acorda Therapeutics Inc. recently announced that the United States District Court for the District of Delaware invalidated four of its patents related to Ampyra extended release tablets. Read More »
Incyte, Merck launch studies examining combination of cancer drugs
Incyte Corp. and Merck have initiated a clinical development program that will examine the possibility of combining epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN). Read More »
Mylan acquires global rights to Cold-EEZE family of products
Mylan N.V. has acquired the global rights to Cold-EEZE, a cold remedy line of products, from ProPhase Labs Inc. Read More »
White paper released on latex allergy risks in health care
Allergy & Asthma Network and Avella Specialty Pharmacy have released a white paper underscoring latex allergy risks and how that relates to the health care industry. Read More »
Alerts Sign-up